Described by experts as the ‘closest we have ever been to a HIV vaccine’, a twice-yearly HIV prevention injection called lenacapavir is set to hit the market. Yet, despite participating in medical trials, many Latin American countries will be banned from accessing the drug’s affordable generic version.
Of the almost 40 million people living with HIV, more than 31 million are on life-saving antiretroviral treatment. However, prevention efforts have suffered, and transmission is on the rise in at least 28 countries, according to UNAIDS.
